{"id":"karx-ec","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The exact mechanism of action for KarX-EC is not publicly disclosed in available sources. As a Phase 3 candidate from Bristol-Myers Squibb, it represents an investigational therapy in development, but specific molecular targets and mechanistic details remain proprietary or under investigation.","oneSentence":"KarX-EC is an extended-release formulation designed to improve the pharmacokinetic profile and therapeutic delivery of its active component.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:47.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07424404","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2026-03-31","conditions":"Schizophrenia, Autism-Related Irritability","enrollment":400},{"nctId":"NCT06976216","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-14","conditions":"Alzheimer's Disease","enrollment":586},{"nctId":"NCT07011732","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-10","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT06937229","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-02","conditions":"Alzheimer Disease, Agitation","enrollment":600},{"nctId":"NCT06976203","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-21","conditions":"Alzheimer's Disease","enrollment":586},{"nctId":"NCT07011745","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-16","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT07284745","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07285798","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07063342","phase":"PHASE1","title":"A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-27","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT06853171","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-04-29","conditions":"Psychiatric Disorders","enrollment":24},{"nctId":"NCT06605950","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-10-01","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT06947941","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-31","conditions":"Alzheimer Disease, Psychosis","enrollment":1046}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-986519","Xanomeline Enteric-coated","Xanomeline enteric capsules, BMS-986519"],"phase":"phase_3","status":"active","brandName":"KarX-EC","genericName":"KarX-EC","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}